Skip to main content
Top
Published in: Journal of Neurology 3/2010

01-03-2010 | Original Communication

Early onset probable linezolid-induced encephalopathy

Authors: Jeffery Fletcher, Laura E. Aykroyd, Eric C. Feucht, James M. Curtis

Published in: Journal of Neurology | Issue 3/2010

Login to get access

Abstract

Linezolid is increasingly being utilized for the treatment of Gram-positive pathogens. While neurological complications with linezolid are rare, long-term exposure can be associated with neurotoxic effects. Patients with pre-existing neurologic sequelae or risk factors, such as alcohol abuse, diabetes, or concomitant administration of chemotherapeutic agents and/or antiretroviral therapy, may be more susceptible to the development of linezolid-induced neurotoxicity. We describe a 41-year-old male who developed early onset encephalopathy after a day and a half of linezolid therapy. Our patient had at least one significant risk factor (alcoholism), making linezolid-induced encephalopathy probable based upon the Naranjo probability scale. Clinicians should be aware of the potential for early onset linezolid-induced neurotoxicity, particularly in patients with concomitant risk factors.
Literature
1.
go back to reference Pharmacia & Upjohn. Zyvox (linezolid) package insert. Kalamazoo, MI 2000 (revised 2006) Pharmacia & Upjohn. Zyvox (linezolid) package insert. Kalamazoo, MI 2000 (revised 2006)
2.
go back to reference Bishop E, Melvani S, Howden BP, Charles PG, Grayson MI (2006) Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother 50:1599–1602CrossRefPubMed Bishop E, Melvani S, Howden BP, Charles PG, Grayson MI (2006) Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother 50:1599–1602CrossRefPubMed
3.
go back to reference Kopterides P, Papadomichelakis E, Armaganidis A (2005) Linezolid use associated with lactic acidosis. Scand J Infect Dis 37:153–154CrossRefPubMed Kopterides P, Papadomichelakis E, Armaganidis A (2005) Linezolid use associated with lactic acidosis. Scand J Infect Dis 37:153–154CrossRefPubMed
4.
go back to reference Ferry T, Ponceau B, Simon M, Issartel B, Petiot P et al (2005) Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases. Infection 33(3):151–154CrossRefPubMed Ferry T, Ponceau B, Simon M, Issartel B, Petiot P et al (2005) Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases. Infection 33(3):151–154CrossRefPubMed
5.
go back to reference Nagel S, Kohrmann M, Huttner HB, Storch-Hagenlocher B et al (2007) Linezolid-induced posterior reversible leukoencephalopathy syndrome. Arch Neurol 64(5):746–748CrossRefPubMed Nagel S, Kohrmann M, Huttner HB, Storch-Hagenlocher B et al (2007) Linezolid-induced posterior reversible leukoencephalopathy syndrome. Arch Neurol 64(5):746–748CrossRefPubMed
6.
go back to reference Azamfirei L, Copotoiu SM, Branzaniuc K, Szederjesi J et al (2007) Complete blindness after optic neuropathy induced by short-term treatment in a patient suffering from muscle dystrophy. Pharmacoepidemiol Drug Saf 16(4):402–404CrossRefPubMed Azamfirei L, Copotoiu SM, Branzaniuc K, Szederjesi J et al (2007) Complete blindness after optic neuropathy induced by short-term treatment in a patient suffering from muscle dystrophy. Pharmacoepidemiol Drug Saf 16(4):402–404CrossRefPubMed
7.
go back to reference Narita M, Tsuji BT, Yu VL (2007) Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 27(8):1189–1197CrossRefPubMed Narita M, Tsuji BT, Yu VL (2007) Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 27(8):1189–1197CrossRefPubMed
8.
go back to reference De Vriese AS, Coster RV, Smet J, Seneca S, Lovering A et al (2006) Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis. 42(8):1111–1117CrossRefPubMed De Vriese AS, Coster RV, Smet J, Seneca S, Lovering A et al (2006) Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis. 42(8):1111–1117CrossRefPubMed
9.
go back to reference Soriano A, Miro O, Mensa J (2005) Mitochondrial toxicity associated with linezolid [letter]. N Engl J Med 353:2305–2306CrossRefPubMed Soriano A, Miro O, Mensa J (2005) Mitochondrial toxicity associated with linezolid [letter]. N Engl J Med 353:2305–2306CrossRefPubMed
10.
go back to reference Palenzuela L, Hahn NM, Nelson RP, Arno JN, Schobert C et al (2005) Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis 40:e113–e116CrossRefPubMed Palenzuela L, Hahn NM, Nelson RP, Arno JN, Schobert C et al (2005) Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis 40:e113–e116CrossRefPubMed
11.
go back to reference Leach KL, Swaney SM, Colca JR, McDonald WG, Blinn JR et al (2007) The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell 26(3):393–402CrossRefPubMed Leach KL, Swaney SM, Colca JR, McDonald WG, Blinn JR et al (2007) The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell 26(3):393–402CrossRefPubMed
12.
go back to reference McKee EE, Ferguson M, Bentley AT, Marks TA (2006) Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother 50(6):2042–2049CrossRefPubMed McKee EE, Ferguson M, Bentley AT, Marks TA (2006) Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother 50(6):2042–2049CrossRefPubMed
13.
go back to reference Myrianthefs P, Markantonis SL, Vlachos K, Anagnostaki M et al (2006) Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother 50(12):3971–3976CrossRefPubMed Myrianthefs P, Markantonis SL, Vlachos K, Anagnostaki M et al (2006) Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother 50(12):3971–3976CrossRefPubMed
14.
go back to reference Gill CJ, Murphy MA, Hamer DH (2002) Treatment of Staphylococcus epidermidis ventriculo-peritoneal shunt infection with linezolid. J Infect 45:129–132CrossRefPubMed Gill CJ, Murphy MA, Hamer DH (2002) Treatment of Staphylococcus epidermidis ventriculo-peritoneal shunt infection with linezolid. J Infect 45:129–132CrossRefPubMed
15.
go back to reference Caplin LR (2006) Cardiac encephalopathy and congestive heart failure. A hypothesis about the relationship. Neurology 66:99–101CrossRef Caplin LR (2006) Cardiac encephalopathy and congestive heart failure. A hypothesis about the relationship. Neurology 66:99–101CrossRef
16.
go back to reference Naranjo CA, Busto U, Sellers EM et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239–245PubMed Naranjo CA, Busto U, Sellers EM et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239–245PubMed
Metadata
Title
Early onset probable linezolid-induced encephalopathy
Authors
Jeffery Fletcher
Laura E. Aykroyd
Eric C. Feucht
James M. Curtis
Publication date
01-03-2010
Publisher
Springer-Verlag
Published in
Journal of Neurology / Issue 3/2010
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-009-5340-y

Other articles of this Issue 3/2010

Journal of Neurology 3/2010 Go to the issue